MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding MiNK Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 13 | 11 | −2 |
| Shares | 357.4K | 475.7K | +118.3K (+33.1%) |
| Value | $504.0K | $1.00M | +$499.0K (+99.0%) |
New holders (5)
Institutions that held MiNK Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| First Republic Investment Management, Inc. | 81,500 | $172.0K | 0.00% |
| Vanguard Group Inc | 49,107 | $104.0K | 0.00% |
| State Street Corp | 11,109 | $23.0K | 0.00% |
| HighTower Advisors, LLC | 10,400 | $22.0K | 0.00% |
| Royal Bank of Canada | 468 | $1.00K | 0.00% |
Sold out (7)
Institutions that held MiNK Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Bridgeway Capital Management, LLC | 35,500 | $50.0K |
| Tower Research Capital LLC (TRC) | 1,104 | $2.00K |
| FMR LLC | 374 | $1.00K |
| JPMorgan Chase & Co | 247 | $0 |
| Bank of America Corp | 1 | $0 |
| Credit Suisse AG | 1 | $0 |
| Citigroup Inc | 21 | $0 |